What is the maximum recommended dose of daridorexant for patients over 70 years of age?

Maximum Recommended Dose of Daridorexant in Patients Over Age 70

The maximum recommended dose of daridorexant for patients over 70 years of age is 50 mg once nightly, with no dose reduction required based on age alone. 1

FDA-Approved Dosing

The FDA prescribing information for daridorexant (QUVIVIQ) clearly states that the recommended dosage is 25 mg to 50 mg once per night for all adult patients, taken orally within 30 minutes before going to bed, with at least 7 hours remaining prior to planned awakening 1. Importantly, age alone does not necessitate dose adjustment—the pharmacokinetic studies demonstrate that age, sex, race, and body size did not have clinically significant effects on daridorexant pharmacokinetics 1.

Evidence Supporting Full Dosing in Older Adults

A dedicated secondary analysis of phase 3 trial data specifically examined patients ≥65 years (n=364) compared to younger adults 2. This analysis demonstrated that:

• Daridorexant 50 mg provided maximal efficacy in older adults for both nighttime sleep parameters and daytime functioning
• At month 3, daridorexant 50 mg decreased wake after sleep onset (WASO) by 19.6 minutes in older patients versus 17.4 minutes in younger patients
• The 50 mg dose improved daytime functioning (IDSIQ scores) progressively from week 1 onward in older adults, while the 25 mg dose only improved daytime functioning in younger adults
• The safety profile was comparable between age groups, with no increased risk of adverse events in older patients
• There was no increased risk of falls in older adults taking daridorexant compared to placebo

Safety Considerations Specific to Older Adults

The evidence shows that older patients are not at increased risk for:

• Residual morning sedation or impairment 2
• Falls (actually fewer falls occurred on daridorexant than placebo) 2
• Complex sleep behaviors (only one case of sleep paralysis reported, no narcolepsy, cataplexy, or complex sleep behaviors in older adults) 2

Dose Modifications: When They ARE Required

While age alone does not require dose reduction, dose adjustment IS necessary for:

• Moderate hepatic impairment (Child-Pugh score 7-9): Maximum dose 25 mg once nightly 1
• Severe hepatic impairment (Child-Pugh score ≥10): Not recommended 1
• Concomitant moderate CYP3A4 inhibitors: Maximum dose 25 mg 1
• Concomitant strong CYP3A4 inhibitors: Avoid use entirely 1

Renal impairment does not require dose adjustment, even in severe renal impairment (creatinine clearance <30 mL/min, not on dialysis) 1.

Clinical Algorithm for Dosing in Patients Over 70

1. Start with 50 mg unless contraindications exist
2. Check for hepatic impairment: If moderate, use maximum 25 mg; if severe, do not use
3. Review concomitant medications: Adjust for CYP3A4 inhibitors as noted above
4. No adjustment needed for: Age alone, renal impairment, or body weight

Common Pitfall to Avoid

Do not automatically reduce the dose in older adults based on age alone. This is a critical distinction from many other sedative-hypnotics (such as benzodiazepines, where guidelines recommend dose reduction in elderly patients 3). The pharmacokinetic profile of daridorexant, with its 8-hour half-life and lack of accumulation, combined with the specific evidence in older adults, supports full-dose use 2, 4, 5.

The 50 mg dose is particularly important for older adults to achieve meaningful improvements in daytime functioning, which is often significantly impaired in this population with insomnia 2.